BioSpace News Archive

Clover Biopharmaceuticals announced the completion of targeted enrollment of adult and elderly participants in SPECTRA, a global pivotal Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of SCB-2019, Clover’s COVID-19 vaccine candidate.

The rise in target patient population is considered a key factor boosting the global gene expression market and likely to continue doing so in the forecast period set between 2020 and 2030.

Blepharitis is an inflammatory condition of the eyelid, which causes ocular discomfort and irritation in all age groups of the population.

The canes and crutches market analysis offers insights into demand outlook in terms of product and distribution channel.

The cardiac ablation technologies market survey offers insights into chief growth drivers and restrains impacting the overall growth trajectory.

Inbiose, a leading biotech company active in the development of Human Milk Oligosaccharides, is pleased to announce that it has submitted its application for a Generally Recognized as Safe approval by the US Food & Drug Administration of four HMOs, specifically 6'-Sialyllactose, 3-Sialyllactose, Lacto-N-Tetraose and Lacto-N-neoTetraose.

Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, provided the following corporate update:

Advaxis, Inc. and Biosight Ltd., a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, announced that the companies have entered into a definitive merger agreement pursuant to which the shareholders of Biosight will become the majority holders of the combined company immediately following completion of the transaction.

Seegene announced on July 1 that it has signed a partnership with Bio-Rad, laboratories, Inc. for the clinical development and commercialization of infectious disease molecular diagnostic products.

IVERIC bio, Inc. announced that the Company received written agreement from the U.S. Food and Drug Administration under a Special Protocol Assessment for the overall design of GATHER2, the Company’s pivotal clinical trial of Zimura® in development for the treatment of geographic atrophy secondary to age-related macular degeneration.